EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Real‐World Safety and Efficacy of Pola‐R‐ CHP in Previously Untreated DLBCL : POLASTAR Interim Analysis of 500 Patients

Takahiro Kumode iD, Hitomi Sawa, Kohta Miyawaki iD, Atsushi Satake iD, Nobuhiro Kanemura, Ritsuro Suzuki iD, Yuki Fujiwara, Yasuhiro Nagate, Shuichi Ota, Takahiro Fujino, Hideki Goto iD, Noriko Fukuhara iD und 10 weitere

Cancer Science · 2026-11 · 117 (11) · 3098-3107

DOI: 10.1111/cas.70484 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Science, online erschienen am 24.07.2026. Verfasst von Takahiro Kumode und 21 weiteren Autor:innen. Beteiligte Einrichtung: Kindai University Faculty of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Large B-Cell, Diffuse. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chugai Pharmaceutical Co., Ltd, Chugai Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

POLASTAR (jRCT1071220082) is a multicenter, prospective observational study evaluating the real‐world efficacy and safety of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone (Pola‐R‐CHP) in Japanese patients with diffuse large B‐cell lymphoma (DLBCL), addressing the limited real‐world data in this setting. Patients ≥ 18 years, with previously untreated DLBCL, receiving Pola‐R‐CHP were enrolled. Patients excluded from POLARIX (NCT03274492), including those > 80 years, were included. Overall, 485 patients were included in the full analysis set (FAS; median age, 71 years [range 27–93]; age ≤ 80 years, 87.6%; International Prognostic Index score 2–5, 73.7%). Median relative dose intensity (RDI) for rituximab and polatuzumab vedotin was ≥ 93.0% (both FAS and patients > 80 years), and for the chemotherapy components median RDI was ≥ 87.2% in the FAS and ≥ 49.6% for patients > 80 years. Grade ≥ 3 adverse events (AEs) occurred in 47.4% of patients in the FAS and 56.7% of patients > 80 years; serious AEs occurred in 12.6% and 25.0%, respectively. The most common Grade ≥ 3 AE (FAS/> 80 years) was neutrophil count decreased (25.6%/26.7%). In the FAS, 5 (1.0%) deaths due to AEs were reported and 33 (6.8%) patients discontinued polatuzumab vedotin due to AEs. No new safety signals were observed. In the FAS, overall response rate and complete response rate (95% confidence interval [CI]) were 93.2% (90.5–95.2) and 83.3% (79.6–86.5), respectively, and were 87.3% (76.0–93.7) and 80.0% (67.6–88.4) in patients > 80 years. Safety and efficacy of Pola‐R‐CHP in Japanese patients, including those > 80 years, were consistent with results from POLARIX. Trial Registration: Japan Registry of Clinical Trials (jRCT1071220082)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, Large B-Cell, DiffuseHumansFemaleAgedMaleAged, 80 and overMiddle AgedAdultDoxorubicinRituximabCyclophosphamideAntibodies, MonoclonalPrednisoloneProspective StudiesTreatment OutcomeImmunoconjugates

Stichwörter der Autor:innen

DLBCLPola‐R‐CHPelderly patientspolatuzumab vedotinreal‐world data

Substanzen

DoxorubicinRituximabCyclophosphamideAntibodies, MonoclonalPrednisolonepolatuzumab vedotinImmunoconjugates

Autor:innen und Institutionen

  • Kindai University Faculty of Medicine, Osaka, Japan.
  • Anjo Kosei Hospital, Aichi, Japan.
  • Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
  • Kansai Medical University, Hirakata, Japan.
  • Gifu University Hospital, Gifu, Japan.
  • Shimane University Hospital, Izumo, Japan.

ORCID-Profile: Takahiro Kumode, Kohta Miyawaki, Atsushi Satake, Ritsuro Suzuki, Hideki Goto, Noriko Fukuhara, Mamiko Sakata-Yanagimoto, Koji Izutsu, Momoko Nishikori, Itaru Matsumura, Koji Kato

Förderung

  • Chugai Pharmaceutical Co., Ltd
  • Chugai Pharmaceutical

Zitieren

APA

Kumode, T., Sawa, H., Miyawaki, K., Satake, A., Kanemura, N., Suzuki, R., Fujiwara, Y., Nagate, Y., Ota, S., Fujino, T., Goto, H., Fukuhara, N., Sakata-Yanagimoto, M., Izutsu, K., Nishikori, M., Shibayama, H., Ennishi, D., Shimose, T., Asai, M., …, & Kato, K. (2026). Real‐World Safety and Efficacy of Pola‐R‐ CHP in Previously Untreated DLBCL : POLASTAR Interim Analysis of 500 Patients. Cancer Science, 117(11), 3098-3107. https://doi.org/10.1111/cas.70484

Vancouver

Kumode T, Sawa H, Miyawaki K, Satake A, Kanemura N, Suzuki R, et al. Real‐World Safety and Efficacy of Pola‐R‐ CHP in Previously Untreated DLBCL : POLASTAR Interim Analysis of 500 Patients. Cancer Science. 2026;117(11):3098-3107. doi:10.1111/cas.70484

BibTeX
@article{Kumode2026,
  author = {Kumode, Takahiro and Sawa, Hitomi and Miyawaki, Kohta and Satake, Atsushi and Kanemura, Nobuhiro and Suzuki, Ritsuro and Fujiwara, Yuki and Nagate, Yasuhiro and Ota, Shuichi and Fujino, Takahiro and Goto, Hideki and Fukuhara, Noriko and Sakata-Yanagimoto, Mamiko and Izutsu, Koji and Nishikori, Momoko and Shibayama, Hirohiko and Ennishi, Daisuke and Shimose, Takayuki and Asai, Mai and Matsumura, Itaru and Akashi, Koichi and Kato, Koji},
  title = {Real‐World Safety and Efficacy of Pola‐R‐ CHP in Previously Untreated DLBCL : POLASTAR Interim Analysis of 500 Patients},
  journal = {Cancer Science},
  year = {2026},
  volume = {117},
  number = {11},
  pages = {3098--3107},
  doi = {10.1111/cas.70484}
}
Kostenlos starten →